Lancaster General Health Receives First Commercial InCise™ Multileaf Collimator for the CyberKnife® M6™ System

News provided by

Feb 24, 2015, 09:00 ET

SUNNYVALE, Calif. and LANCASTER, Pa., Feb. 24, 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) and Lancaster General Health announced today that the first commercially available InCise™ Multileaf Collimator (MLC) for the CyberKnife^® M6™ System has been received by Lancaster. The hospital selected the InCise MLC based on its ability to increase the system's treatment efficiency and extend its unique capabilities to a broader range of patient cases.

Evaluation of the InCise MLC with the CyberKnife M6 system has been successfully completed by two U.S. sites. Accuray conducted a rigorous evaluation of the device covering a wide range of functionality, performance, reliability and serviceability parameters. The InCise MLC successfully met all predetermined criteria to the company's and the sites' full satisfaction. Accuray is now working closely with its supply chain network to scale up manufacturing to meet commercial demand for the MLC.

The InCise MLC is the world's first multileaf collimator to be available on a robotic platform, the CyberKnife M6 System. The system was designed to deliver extremely precise stereotactic body radiation therapy (SBRT). Using its unique robotic range of motion and continuous image guidance, the system follows the target throughout the treatment process, delivering individualized treatment with sub-millimeter precision. The CyberKnife M6 System can be used to treat tumors anywhere in the body, including the prostate, lung, brain, spine, liver, pancreas and kidney, and may offer hope to patients who have inoperable or surgically complex tumors, or who may prefer a clinically effective, non-surgical option.

"This is an important milestone for Accuray. It represents an evolution in the CyberKnife System platform that we believe will lead to meaningful improvements in the treatment of cancer for clinicians and patients, and broaden the range of patients and tumors that can be treated," said Joshua H. Levine, president and chief executive officer of Accuray. "For example, evaluations to date of the technical performance of the device indicate that its use may result in a 30% to 40% reduction in treatment times compared to current timeframes. Patients will experience enhanced comfort from spending less time on the treatment couch and clinicians will see efficiencies in their ability to plan and deliver SBRT."

"We look forward to treating our first patient using the newly configured CyberKnife M6 System. With the MLC we expect to reduce SBRT treatment times without sacrificing the precision we've come to expect from the system," said Jeffrey Eshleman, MD, Director of Radiation Oncology, Lancaster General Health. "In addition, the InCise MLC will expand patient access to SBRT to those people who previously may not have been eligible due to the size or type of their tumor. SBRT is typically a much shorter course of treatment than conventional radiation therapy. It has the potential to reduce the overall cost of patient care, and discomfort and scheduling inconvenience for the patient, versus conventional treatment."

About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments.

Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to advantages of new technology, clinical applications, clinical results, patient outcomes, successful adoption of Accuray technologies, and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 29, 2014, the company's reports on Form 10-Q, filed on November 7, 2014 and February 6, 2015, and the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

About Lancaster General Health
Lancaster General Health is a three-hospital not-for-profit health system located in South Central Pennsylvania. Members of the LG Health system include the 533-bed Lancaster General Hospital (LGH), the 97-bed Women & Babies Hospital, and the 59-bed Lancaster Rehabilitation Hospital. Outpatient services are provided at 14 outpatient centers, including Downtown and Suburban Outpatient Pavilions, three Urgent Care sites and an LG Health Express location. Lancaster General Health Physicians includes nearly 200 primary-care and specialist physicians at nearly 40 practices throughout South Central PA.

Thrice designated a Magnet hospital for nursing excellence, LGH has been recognized regionally and nationally for clinical excellence and patient safety. Open-heart-surgery outcomes at its Lancaster Heart & Vascular Institute are among the best in the nation. Women & Babies offers comprehensive services including deliveries, GYN services, surgical care and a 29-bed Neonatal Intensive Care Unit offering South Central PA's most advanced care for newborns with extreme prematurity, acute low-birth weight and severe or complex illnesses.

The system's Ann B. Barshinger Cancer Institute is the only provider in Central PA to offer multimodality radiosurgery, including Gamma Knife^®, TomoTherapy^®, CyberKnife^® M6™ and TrueBeam™ technology via an integrated-care approach. The system's Pennsylvania College of Health Sciences is a private, co-educational, Middle States-accredited four-year college offering a variety of associate and baccalaureate degree and certification programs in healthcare.

SOURCE Accuray Incorporated